Company / FCF Margin
Halozyme FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
46.2%
FY2025
5-year range
-45.6% / 46.2%
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#5 of 133
Health Care
What the data says
Among 133 Health Care companies, Halozyme is in the top 4% for fcf margin. FCF Margin has increased for 4 consecutive years, from -45.6% in FY2021 to 46.2% in FY2025.
Based on SEC 10-K filings.
46.2% in FY2025 with a 5-year CAGR of +81.8%. Top quartile in the Health Care sector.
Improved from 45.0% to 46.2% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +10.5pp
- 5-Year Change
- +81.8pp
- 10-Year Change
- -
Sector benchmark
Top 4% in Health CareTop 4% of 133This company 46.2% Sector average -632.8%
▼
+107.3% above sector average
Key checks
Key Insights
- Halozyme's fcf margin has grown for 4 consecutive years.
- In FY2025, fcf margin increased 0.0% year-over-year.
- Currently 679.0pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2019.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 46.2% | +0.0% |
| FY2024 | 46.1% | +2.5% |
| FY2023 | 45.0% | +26.3% |
| FY2022 | 35.6% | +178.1% |
| FY2021 | -45.6% | -28.0% |
| FY2020 | -35.7% | -115.3% |
| FY2019 | 233.0% | +232.8% |
| FY2018 | -175.4% | -518.6% |
| FY2017 | 41.9% | +164.6% |
| FY2016 | -64.9% | +31.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026